Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Affiliations

• ¹ Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
• ² Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Jhanelle.Gray@moffitt.org.
• ³ Jilin Provincial Cancer Hospital, Changchun, China.
• ⁴ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
• ⁵ Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
• ⁶ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
• ⁷ Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan.
• ⁸ Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
• ⁹ Kent Oncology Centre, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
• ¹⁰ Oncology R&D, AstraZeneca, Cambridge, UK.
• ¹¹ Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK.
• ¹² Winship Cancer Institute, Emory University, Atlanta, GA, USA.